Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Expands By 120.7%

Key Points

• Short interest more than doubled to 3.75 million shares as of July 15, up 120.7% from June 30. Short interest represents 9.6% of outstanding shares, equivalent to 5.5 days of average trading volume.
• ZSQR opened at $4.81, near its 12-month low of $4.32 and well below its 50-day and 200-day moving averages. The company reported a quarterly loss of $0.65 per share, $0.11 million in revenue, and sharply negative profitability metrics.
• Analyst sentiment is bearish: Wall Street Zen downgraded the stock from “hold” to “sell,” leaving Coeptis with a consensus “Sell” rating from the one analyst covering it.

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 3,746,865 shares, an increase of 120.7% from the June 30th total of 1,697,593 shares. Based on an average daily trading volume, of 686,566 shares, the short-interest ratio is presently 5.5 days. Currently, 9.6% of the company's shares are sold short.

Coeptis Therapeutics Price Performance

Shares of ZSQR stock opened at $4.81 on Tuesday. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics has a 12-month low of $4.32 and a 12-month high of $21.41. The firm has a fifty day moving average of $9.78 and a 200-day moving average of $11.65. The firm has a market capitalization of $247.38 million, a price-to-earnings ratio of -1.91 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR - Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Analysts Set New Price Targets

Separately, Wall Street Zen cut Coeptis Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics has a consensus rating of "Sell".

Institutional Investors Weigh In On Coeptis Therapeutics

A number of hedge funds have recently modified their holdings of ZSQR. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics in the 4th quarter valued at approximately $259,000. State Street Corp raised its holdings in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company's stock worth $382,000 after buying an additional 6,962 shares during the period. Geode Capital Management LLC lifted its stake in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company's stock valued at $600,000 after buying an additional 4,721 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company's stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 13.88% of the company's stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.